ST
STME.US STME
- Market cap
- USD 6.34M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Aug 2026.
Is STME.US undervalued?
Graham numberThe Graham number of STME cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
STME fundamental analysis
No fundamental analysis for STME yet.
STME stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About STME
StimCell Energetics Inc., a biotech company, discovers, develops, and commercializes therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, metabolic syndrome, neuropathy, and kidney functions in the United States. It develops and manufactures the eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and the eBalance Home System for home use for general wellness and pain management …
Full company profileSTME financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Aug 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
STME annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.22K | - | 95.8K | 95.8K | 6.07K | 6.07K | 2.76K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.17K | -580.00 | 85.6K | 85.6K | 4.03K | 4.03K | 483.00 | 0.00 | - | - | - |
| Operating Income | -1.56M | -1.54M | -1.04M | -1.04M | -672K | -672K | -448K | -313K | -505K | -821K | -559K |
| EBITDA | -1.07M | -1.38M | -670K | -1.04M | -876K | - | -447K | -7.08K | -528K | -821K | -559K |
| Net Income | -1.25M | -1.55M | -923K | -1.09M | -911K | -697K | -495K | -142K | -566K | -895K | -678K |
| EPS | -0.03 | -0.04 | -0.02 | -0.02 | -0.02 | -0.17 | -0.01 | 0.00 | -0.03 | -0.04 | -0.03 |
| Balance Sheet | |||||||||||
| Total Assets | 294K | 45.3K | 191K | 159K | 52.2K | 41.3K | 103K | 46.1K | 21.2K | 81.5K | 60.9K |
| Total Liabilities | 1.46M | 1.12M | 1.96M | 1.68M | 1.63M | 2.05M | 2.49M | 873K | 1.27M | 1.89M | 2.03M |
| Shareholders' Equity | -1.17M | -1.07M | -1.77M | -1.52M | -1.58M | -2.01M | -2.39M | -826K | -1.25M | -1.81M | -1.97M |
| Cash & Short-term Investments | 67.5K | 8.20K | 57.2K | 45.1K | 20.8K | 24.4K | 98.3K | 43.4K | 14.6K | 3.06K | 6.88K |
| Total Debt | 541K | 117K | 512K | 502K | 617K | - | 1.00M | 313K | 459K | 691K | 802K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -754K | -449K | -308K | -926K | -560K | -451K | -272K | -146K | -142K | -312K | -436K |
| Capital Expenditure | 110K | 0.00 | 1.92K | 2.46K | 1.57K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 16.00 |
| Free Cash Flow | -864K | -449K | -309K | -928K | -562K | -451K | -272K | -146K | -142K | -312K | -436K |
| Ratios | |||||||||||
| ROA | -425.4% | -3,417.7% | -484.3% | -686.5% | -1,743.5% | -1,686.8% | -479.4% | -308.9% | -2,668.4% | -1,099.2% | -1,112.6% |
| Net Profit Margin | -20,087.6% | - | -962.9% | -1,140.3% | -15,017.9% | -11,498.4% | -17,923.3% | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
STME dividends
STME has not paid dividends in the last 9 fiscal years.
Last stock split: 1:15 on Nov 5, 2024.
Who owns STME
- Insiders 71.67%
- Institutions 0.00%
- Public & others 28.33%
- Shares outstanding 21.1M
- Free float 5.94M
STME company profile
- Company name
- STME
- Ticker
- STME.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Medical Devices
- Fiscal year end
- May
- Address
- 1130 Pender Street, West, Vancouver, BC, Canada, V6E 4A4
- Phone
- 844 238 2692
- Website
- stimcell.com
About STME
StimCell Energetics Inc., a biotech company, discovers, develops, and commercializes therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, metabolic syndrome, neuropathy, and kidney functions in the United States. It develops and manufactures the eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and the eBalance Home System for home use for general wellness and pain management treatment, which are controlled by the eBalance Console that acts as the central controller for three pre-programmed microcurrent algorithms, including wellness, pain management, and dual. The company also develops eBalance Home and eBalance Pro System for temporary relief of the shoulder, waist, back, neck, upper and lower extremities (arms and legs). The company was formerly known as Cell MedX Corp. and changed its name to StimCell Energetics Inc. in November 2024. StimCell Energetics Inc. was incorporated in 2010 and is headquartered in Vancouver, Canada.
STME management
1- Mr. David M. JeffsPresident, CEO & Director · born 1970